Skip to Content

Shacey Petrovic, a director of Insulet Co. (NASDAQ:PODD), sells 15,000 shares.

Shacey Petrovic, a director of Insulet Co. (NASDAQ:PODD), sells 15,000 shares.

On January 4, Insulet Co. (NASDAQ: PODD) director Stacey Petrovic made a transaction in which she sold 15,000 shares of the company’s stock. The total value of the sold shares was $4,228,200.00, and the price received for each one was an average of $281.88. Following the completion of the sale, the director now owns a total of 14,789 shares in the corporation, which have a combined value of $4,168,723.32 at present. In addition, the Securities and Exchange Commission was given legal documentation about the transaction, which can be viewed entirely by following the link provided in the previous sentence. The documentation was provided to the SEC.
On November 3, Insulet (NASDAQ: PODD) provided the general public with a report detailing its quarterly results. The manufacturer of medical supplies and devices reported earnings per share for the quarter of $0.45, which was $0.28 more than the consensus estimate of $0.17. During its fiscal year, Insulet was able to generate a net margin of 1.35% and an equity return of 18.19%. Analysts’ revenue projections for the upcoming quarter varied widely, ranging from $311.84 million to $340.80 million in total. Insulet Company is expected to generate $0.99 in earnings per share for the current fiscal year, according to projections made by industry analysts.
A significant number of research organizations have brought up the topic of PODD. Before the publication of the research note by BTIG Research on November 4, the price objective for Insulet’s stock was set at $285.00 per share; after the publication of the note, the price objective was increased to $320.00 per share. The rating for Insulet was changed by Piper Sandler on November 4, moving it from “neutral” to “overweight” in the process. In addition, the price target they had set for the stock increased from $235.00 to $340.00. The price target that Barclays has set for Insulet has increased from $238.00 to $245.00 due to a research note published on Wednesday. Robert W. Baird raised the price objective for Insulet in a research report published on Monday, December 12. The new price objective is $340.00, an increase from the previous price objective of $315.00. Insulet was the subject of the report. In a research report published on Friday but made available to the public on November 4, Raymond James gave the stock an “outperform” rating. The report on which the rating was based was made public on Friday. The price target that Raymond James has set for Insulet shares has increased from $280.00 to $320.00 before the announcement that will be made. Nine market watchers have assigned the stock a “buy” rating, while only five have assigned it a “hold” rating. According to information made available by Bloomberg.com, the general opinion regarding the company is that it currently warrants a “Moderate Buy” rating, and the general opinion regarding the price target for the company is that it should be $309.23.
On Friday, the closing price for NASDAQ PODD was $292.31, reflecting an increase of $6.15 throughout the trading session. Three hundred ninety-eight seven hundred forty-five shares were traded, lower than the typical daily volume of 476,786 during the trading session. In total, 398,745 shares were traded, which is lower than the typical daily volume of 476,786. The stock price of Insulet Company has ranged from a one-year low of $181.00 to a one-year high of $320.00 over the past year. The company has a beta value of 0.79 and a price-to-earnings ratio of 1,195.08. The company has a market capitalization of $20.30 billion as of right now. The stock price is $293.73 when calculated using the moving average of the previous 50 days, while the price is $260.91 using the moving average of the previous 200 days. A debt-to-equity ratio comes in at 3.22; a quick ratio comes in at 3.00; a current ratio comes in at 3.98; and a quick ratio comes in at 3.00.
As of late, the PODD positions that various hedge funds have held have undergone several different shifts. During the third quarter, Vanguard Group Inc. elevated the proportion of Insulet stock owned by one percent. Vanguard Group Inc. bought an additional 64,742 shares during the most recent fiscal quarter, bringing the total number of shares it owns in the medical equipment supplier up to 6,392,621. These shares are worth a total of $1,466,468,000 collectively. In addition, Clearbridge Investments LLC purchased 38.8 percent of Insulet’s shares during the first three months of 2018. Clearbridge Investments LLC now has 1,696,822 shares of the stock held by the medical equipment provider. This is a result of the company acquiring 474,545 additional shares during the most recent fiscal quarter. The total worth of these shares comes to a total of 452,016,000 dollars. During the second quarter, Echo Street Capital Management LLC increased the number of Insulet shares that it held by 0.6%, bringing the total number of Insulet shares held by the company to a total of 1. Echo Street Capital Management LLC increased its holdings in the stock of the medical instrument supplier by purchasing an additional 5,209 shares during the most recent quarter. As a result of these purchases, the company now owns a total of 807,643 shares of the company’s stock, which has a value of $176,018,000. Through the third quarter, Fred Alger Management LLC was able to amass an additional 1.7% of the total number of Insulet shares outstanding. After making an additional purchase of 10,308 stock units during the most recent fiscal quarter, Fred Alger Management LLC now holds a total of 632,051 units of the common stock of the medical instrument supplier. The current value of these shares on the market is equal to 144,992,000 dollars. In the final step, Goldman Sachs Group Inc. increased the amount of Insulet stock owned by 5.2% during the second quarter. Goldman Sachs Group Inc. now has a total of 616,690 shares of the medical instruments supplier’s stock following the acquisition of an additional 30,411 shares during the most recent quarter. Based on the current stock price, this gives the company a market value of approximately $134,402,000.
Insulet Corporation designs, produce, and sells insulin delivery devices to individuals who have diabetes and are required to take insulin as part of their treatment. Both a portable personal diabetes management system that is wirelessly connected to the Omnipod System, as well as a self-adhesive disposable tubeless Omnipod system that may be worn on the body for up to three days at a time without the need for the adhesive to be reapplied, are provided by this product. The wireless connection between the two systems is accomplished through Bluetooth technology.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *